Collegium Pharmaceutical, Inc. (COLL)
NMS – Real Time Price. Currency in USD
35.69
-0.12 (-0.34%)
At close: May 12, 2026, 4:00 PM EDT
35.10
-0.59 (-1.65%)
After-hours: May 12, 2026, 4:37 PM EDT
Find any stock by ticker or company name

NMS – Real Time Price. Currency in USD
35.69
-0.12 (-0.34%)
At close: May 12, 2026, 4:00 PM EDT
35.10
-0.59 (-1.65%)
After-hours: May 12, 2026, 4:37 PM EDT
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company’s portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
| Name | Position |
|---|---|
| Dr. Thomas B. Smith FAAFP, M.D. | Executive VP & Chief Medical Officer |
| Mr. David Dieter | Executive VP, General Counsel & Corporate Secretary |
| Mr. Dean J. Patras | Chief People Officer |
| Mr. Ian Karp M.B.A. | Head of Investor Relations |
| Mr. Scott Dreyer | Executive VP & Chief Commercial Officer |
| Mr. Scott Sudduth | EVP & Head of Technical Operations |
| Mr. Vikram Karnani | CEO, President & Director |
| Ms. Colleen Tupper | Executive VP & CFO |
| Ms. Jane Gonnerman | Executive Vice President of Strategy & Corporate Development |
| Ms. Jessica Cotrone | Senior Vice President of Communications & Corporate Affairs |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 8-K | coll-20260507.htm |
| 2026-04-07 | DEF 14A | coll-20260407.htm |
| 2026-03-19 | 8-K | tm269336d1_8k.htm |
| 2026-02-26 | 8-K | coll-20260226.htm |
| 2026-02-26 | 10-K | coll-20251231.htm |
| 2026-01-08 | 8-K | tm262493d1_8k.htm |
| 2025-12-30 | 8-K | tm2534421d1_8k.htm |
| 2025-11-06 | 8-K | coll-20251106x8k.htm |
| 2025-11-06 | 10-Q | coll-20250930x10q.htm |
| 2025-08-07 | 8-K | coll-20250807x8k.htm |